Pharsight

Drugs that contain Rifaximin

1. Xifaxan patents expiration

XIFAXAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7612199 SALIX PHARMS Polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(3 months from now)

US7045620 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
Jun, 2024

(3 months from now)

US8835452 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(3 months from now)

US7902206 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(3 months from now)

US8158781 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(3 months from now)

US7906542 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2025

(1 year, 3 months from now)

US8741904 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(2 years from now)

US8193196 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Sep, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158644 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(3 months from now)

US8853231 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(3 months from now)

US7915275 SALIX PHARMS Use of polymorphic forms of rifaximin for medical preparations
Feb, 2025

(11 months from now)

US10703763 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(2 years from now)

US8518949 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(2 years from now)

US9271968 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Feb, 2026

(2 years from now)

US11779571 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS)
Feb, 2029

(5 years from now)

US10456384 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS)
Feb, 2029

(5 years from now)

US10765667 SALIX PHARMS Methods for treating irritable bowel syndrome (IBS)
Feb, 2029

(5 years from now)

US11564912 SALIX PHARMS NA
Feb, 2029

(5 years from now)

US8309569 SALIX PHARMS Methods for treating diarrhea-associated irritable bowel syndrome
Jul, 2029

(5 years from now)

US9629828 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(5 years from now)

US10314828 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(5 years from now)

US9421195 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(5 years from now)

US7928115 SALIX PHARMS Methods of treating travelers diarrhea and hepatic encephalopathy
Jul, 2029

(5 years from now)

US10709694 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(5 years from now)

US8829017 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(5 years from now)

US10335397 SALIX PHARMS Methods of treating hepatic encephalopathy
Jul, 2029

(5 years from now)

US8946252 SALIX PHARMS Methods of treating traveler's diarrhea and hepatic encephalopathy
Jul, 2029

(5 years from now)

US8642573 SALIX PHARMS Methods of treating hepatic encephalopathy
Oct, 2029

(5 years from now)

US8969398 SALIX PHARMS Methods of treating hepatic encephalopathy
Oct, 2029

(5 years from now)

Market Authorisation Date: 25 May, 2004

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (t...

Dosage: TABLET;ORAL

How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage

XIFAXAN family patents

Family Patents